Cargando…
Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management
Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed ove...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781043/ https://www.ncbi.nlm.nih.gov/pubmed/36548935 http://dx.doi.org/10.3390/vision6040073 |
_version_ | 1784856977031036928 |
---|---|
author | Erdinest, Nir London, Naomi Lavy, Itay Landau, David Ben Ephraim Noyman, Dror Levinger, Nadav Morad, Yair |
author_facet | Erdinest, Nir London, Naomi Lavy, Itay Landau, David Ben Ephraim Noyman, Dror Levinger, Nadav Morad, Yair |
author_sort | Erdinest, Nir |
collection | PubMed |
description | Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed over three years. All had a minimum myopia increase of 1.00 D the year prior to treatment. The children were divided into two treatment groups and a control group. One treatment group included 29 children with an average prescription of 4.81 ± 2.12 D (sphere equivalent (SE) range of 1.25–10.87 D), treated with 0.01% atropine for two years (A0.01%). The second group included 26 children with an average prescription of 4.14 ± 1.35 D (SE range of 1.625–6.00 D), treated with MiSight 1 day dual focus contact lenses (DFCL) and 0.01% atropine (A0.01% + DFCL) for two years. The control group included 30 children wearing single-vision spectacles (SV), averaging −5.06 ± 1.77 D (SE) range 2.37–8.87 D). Results: There was an increase in the SE myopia progression in the SV group of 1.19 ± 0.43 D, 1.25 ± 0.52 D, and 1.13 ± 0.36 D in the first, second, and third years, respectively. Myopia progression in the A0.01% group was 0.44 ± 0.21 D (p < 0.01) and 0.51 ± 0.39 D (p < 0.01) in the first and second years, respectively. In the A0.01% + DFCL group, myopia progression was 0.35 ± 0.26 D and 0.44 ± 0.40 D in the first and second years, respectively (p < 0.01). Half a year after the cessation of the atropine treatment, myopia progression (rebound effect) was measured at −0.241 ± 0.35 D and −0.178 ± 0.34 D in the A0.01% and A0.01% + DFCL groups, respectively. Conclusions: Monotherapy low-dose atropine, combined with peripheral blur contact lenses, was clinically effective in decreasing myopia progression. A low rebound effect was found after the therapy cessation. In this retrospective study, combination therapy did not present an advantage over monotherapy. |
format | Online Article Text |
id | pubmed-9781043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97810432022-12-24 Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management Erdinest, Nir London, Naomi Lavy, Itay Landau, David Ben Ephraim Noyman, Dror Levinger, Nadav Morad, Yair Vision (Basel) Article Objectives: To assess the decrease in myopia progression and rebound effect using topical low-dose atropine compared to a combined treatment with contact lenses for myopic control. Methods: This retrospective review study included 85 children aged 10.34 ± 2.27 (range 6 to 15.5) who were followed over three years. All had a minimum myopia increase of 1.00 D the year prior to treatment. The children were divided into two treatment groups and a control group. One treatment group included 29 children with an average prescription of 4.81 ± 2.12 D (sphere equivalent (SE) range of 1.25–10.87 D), treated with 0.01% atropine for two years (A0.01%). The second group included 26 children with an average prescription of 4.14 ± 1.35 D (SE range of 1.625–6.00 D), treated with MiSight 1 day dual focus contact lenses (DFCL) and 0.01% atropine (A0.01% + DFCL) for two years. The control group included 30 children wearing single-vision spectacles (SV), averaging −5.06 ± 1.77 D (SE) range 2.37–8.87 D). Results: There was an increase in the SE myopia progression in the SV group of 1.19 ± 0.43 D, 1.25 ± 0.52 D, and 1.13 ± 0.36 D in the first, second, and third years, respectively. Myopia progression in the A0.01% group was 0.44 ± 0.21 D (p < 0.01) and 0.51 ± 0.39 D (p < 0.01) in the first and second years, respectively. In the A0.01% + DFCL group, myopia progression was 0.35 ± 0.26 D and 0.44 ± 0.40 D in the first and second years, respectively (p < 0.01). Half a year after the cessation of the atropine treatment, myopia progression (rebound effect) was measured at −0.241 ± 0.35 D and −0.178 ± 0.34 D in the A0.01% and A0.01% + DFCL groups, respectively. Conclusions: Monotherapy low-dose atropine, combined with peripheral blur contact lenses, was clinically effective in decreasing myopia progression. A low rebound effect was found after the therapy cessation. In this retrospective study, combination therapy did not present an advantage over monotherapy. MDPI 2022-12-12 /pmc/articles/PMC9781043/ /pubmed/36548935 http://dx.doi.org/10.3390/vision6040073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Erdinest, Nir London, Naomi Lavy, Itay Landau, David Ben Ephraim Noyman, Dror Levinger, Nadav Morad, Yair Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title | Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title_full | Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title_fullStr | Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title_full_unstemmed | Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title_short | Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management |
title_sort | low-concentration atropine monotherapy vs. combined with misight 1 day contact lenses for myopia management |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781043/ https://www.ncbi.nlm.nih.gov/pubmed/36548935 http://dx.doi.org/10.3390/vision6040073 |
work_keys_str_mv | AT erdinestnir lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT londonnaomi lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT lavyitay lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT landaudavid lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT benephraimnoymandror lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT levingernadav lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement AT moradyair lowconcentrationatropinemonotherapyvscombinedwithmisight1daycontactlensesformyopiamanagement |